IPF treatment candidate CS014 was safe and well tolerated in volunteers in a Phase 1 trial, and showed early promise for reversing scarring.| Pulmonary Fibrosis News
GRI Bio reached an interim enrollment goal for a clinical trial testing GRI-0621, a therapy targeting natural killer T-cells to treat IPF.| Pulmonary Fibrosis News